iTeos appoints David Feltquate as chief medical officer

US immune-oncology firm iTeos Therapeutics (Nasdaq: ITOS) today announced the appointment of David Feltquate as chief medical officer (CMO).

In this role, Dr Feltquate will be responsible for overseeing the company’s clinical development and regulatory strategies and brings to iTeos nearly 20 years of immuno-oncology clinical development, translational medicine, and diagnostic assay advancement experience.

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr Feltquate as chief medical officer,” said Michel Detheux, president and chief executive of iTeos. “His leadership experience, track record in immuno-oncology drug development, and insights into biomarker development will prove invaluable as we continue to advance our pipeline. We look forward to the integral role he will play in shaping our clinical development strategy and in strengthening our organization as we continue in a defining year for the company,” he added.